This Cannabis Company Will Likely Beat Q4 Estimates Says Analyst
Trulieve Cannabis Corp. (OTCQX: TCNNF) (CSE:TRUL) will release its fourth quarter and full year 2022 financial results on March 8, 2023.
Recent Activity
Intel Business Model ‘Structurally Misaligned With Industry Direction,’ Analyst Says
Intel Corporation (NASDAQ: INTC) is facing a tough challenge as its business model is said to be "structurally misaligned with industry direction," according to a bearish note issued Sunday by Bank of America Global Securities.
Analyst: How Do Virginia’s Delayed Cannabis Sales Impact Important Deals For These Three MSOs?
Virginia is approaching its second anniversary of legalizing recreational cannabis without a framework for legal sales as yet established.
Cathie Wood Keeps Hoarding This Crypto-Linked Stock: Is It A Buy At Current Levels?
Cathie Wood’s Ark Invest has been consistently accumulating shares of cryptocurrency exchange Coinbase Global, Inc.
Dividend Cut ‘Effectively Unavoidable’: Investing Legend Chanos Lends Megaphone To REIT Skeptic
Real estate investment trusts, or REITs, are generally considered defensive plays because of their steady dividend streams even during times of market volatility.
CareDx Earns Stock Downgrade Amid CMS Coverage Cuts Change Thesis
Raymond James downgraded CareDx Inc (NASDAQ:CDNA) to Market Perform from Strong Buy after MolDX issued a billing and coding article severely limiting coverage…
Xponential Fitness’ Strong Q4 Results & Growth Opportunities Trigger 7% Price Target Boost By This Analyst
Raymond James analyst Joseph Altobello reiterated a Strong Buy rating on the shares of Xponential Fitness Inc (NYSE: XPOF) and raised the price target from $30 to $32.
Analyst Upgrades This Radiology Stock, Expects Promising 2023 Ahead
Raymond James upgraded Radnet Inc (NASDAQ:RDNT) from Market Perform to Outperform and a price target of $30 following 4Q22 results that came in…
Analyst Upgrades This Stock And Doubles Price Target On Encouraging Ibsrela Story
After the market close Thursday, Ardelyx Inc (NASDAQ:ARDX) reported Q4 FY22 Ibsrela sales of $8.7 million and $15.6 million for FY22. The…